Streetbeat News

Analyst Ratings

UBX

HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Unity Biotechnology (NASDAQ:UBX) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:40 am

TRDA

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:39 am

LGND

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Ligand Pharmaceuticals (NASDAQ:LGND) and maintained a price target of $144.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:37 am

SYRS

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Syros Pharmaceuticals (NASDAQ:SYRS) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:36 am

CLDX

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $73.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:35 am

VIGL

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Vigil Neuroscience (NASDAQ:VIGL) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:34 am

KROS

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Keros Therapeutics (NASDAQ:KROS) and maintained a $100 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:34 am

PEPG

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on PepGen (NASDAQ:PEPG) and maintained a price target of $26.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:33 am

ABOS

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:30 am

RVMD

Needham analyst Ami Fadia maintains a 'Buy' rating on Revolution Medicines (NASDAQ:RVMD) but lowers the price target from $35 to $34.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:29 am